Two hundred seventeen patients were studied before and after administration of isoproterenol by IPPB. In 35 patients, lung specimens were examined within 12 months after the study. Patients with elevated bronchial gland-bronchial wall ratio (Reid index showed significantly more improvement in forced expiratory flows after bronchodilator therapy, as compared to patients with normal Reid index. There was no difference in response to therapy in patients with emphysema of less than 20 percent, as compared to patients with emphysema of more than 20 percent. Patients with severe reduction in lung recoil pressure had lesser improvement after therapy in forced expiratory flows, as compared to patients with moderate reduction in recoil pressure or normal recoil pressure. In 39 patients inspiratory pulmonary resistance and forced expiratory flows were measured before and after therapy. In all these 39 patients, airway resistance showed comparable improvement regardless of the value for recoil pressure. The lack of response in expiratory flows is attributed to the increased collapsibilirv of the large airways and not to lack of response to therapy.
"isoproterenol is widely used as a bronchodilator in treatment of patients with chronic obstructive pulmonary disease (COPD). Changes in flow rates after administration of bronchodilators have been advocated as a test to determine the "reversibility" or "irreversibility" of the disease process, 1 to predict which patients will receive benefit from nebulized bronchodilators, 2 and in some reports* lack of response to isoproterenol has been used as a criterion for a diagnosis of emphysema. Others 4 have reported patients with COPD and emphysema (judged on roentgenographic evaluation) as having no changes in forced expired volume in one second (FEVi) after bronchodilator therapy, but significant improvement in inspiratory flow rate. Curtis et al 5 studied the response to bronchodilators in patients with COPD over several years, and found almost all will show improvement in FEVi after use of bronchodilators on one or more occasions. Some patients may show improvement on one study and no change on another. 6 A recent study 7 ported patients responding to bronchodilators had elevated airway resistance, and those with normal airway resistance had no change in flow rates after such therapy. In this report 217 patients were studied before and after administration of isoproterenol through intermittent positive pressure breathing machine (IPPB). In 35 patients lung specimens were available within 12 months after the study, and the response to treatment with bronchodilators was correlated with morphologic emphysema and bronchial gland hyperplasia. Lung recoil pressure and the single breath method diffusing capacity for CO were utilized to divide the patients into those with severe emphysema (50 percent or more), and those without emphysema or with mild emphysema (20 percent or less), 8 and the two groups were compared to ascertain the differences in response to isoproterenol inhalation.
MATERIALS AND METHODS
All patients in this study had FEVi below 80 percent normal. They were referred to the pulmonary function laboratory for evaluation of lung disease, or were a part of a longterm followup study of COPD. The patients were examined and a questionnaire pertaining to the respiratory tract was 
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completed by the examining physician. The study was done in clinically stable patients, and administration of bronchodilators was discontinued ten hours before the test. After completion of bronchodilator therapy, the patient was asked by the technician whether he "improved" or not. During this study only four technicians administered the treatment and did the spirometric studies. All these technicians received adequate training before proceeding on their own. All patients had three forced vital capacity (FVC) curves before the study on a 13.5 L Collins spirometer. Subsequently, they received eight drops of isoproterenol (Isuprel 1:200), diluted by 16 drops of saline, nebulized by IPPB (Bennett PR2). This lasted an average of 10 to 15 minutes. Five minutes after the IPPB was finished, three FVC curves were repeated. Forced expired volume in one second (FEVi) and maximum mid-expiratory flow rate (FEF25-75) were calculated from the record and the highest values used for the study.
On another day, and within a period of a few days, 186 patients had single breath diffusing capacity for carbon monoxide and total lung capacity (TLC) by the closed helium method, 155 patients had lung recoil pressure at total lung capacity (Pst), and 173 patients inspiratory pulmonary resistance. To correct lung recoil pressure for lung volume, percent normal TLC was divided by the value for recoil pressure at total lung capacity {% N TLC/Pst). Methods of pulmonary function and source of normal values have been described in detail previously. 8 lfl Pleural pressure was measured by esophageal balloon, and inspiratory pulmonary resistance was measured at mid-inspiration. Volume and flow were measured by hi-fi Med Science spirometer.
In 25 randomly selected patients airway resistance at 0.5L/sec of flow and lung volumes by constant volume body plethysmograph, 11 recoil pressure at total lung capacity, work of breathing and maximum expiratory flow volume curves (MEFV) were done before and after administration of isoproterenol, in addition to the FVC curve. In an additional 14 patients inspiratory pulmonary resistance was determined before and after use of bronchodilators, in addition tc the studies just mentioned. Work of breathing was calculated from volume-pressure loops recorded on an X-Y recorder. For the MEFV curves, flow and volume from the Ohio Medical spirometer were recorded on a Tektronix storage oscilloscope and photographed. Since flow rates
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change with lung volume, midflow from the FVC curve (FEF25-75) and from MEFV (V max 50 percent VC) were calculated at the same lung volume, assuming there was no change in total lung capacity (Fig 1) . Normal values for TLC and FEVi were taken from the VA Cooperative Study. 12 Inspiratory pulmonary resistance above 4 cm of water per liter per second was considered abnormal. 13 In 35 patients, lung specimens were available within 12 months after the study. There were 5 lobectomies, 12 pneumonectomies, and 18 lungs from autopsies. The surgical specimens were from patients with bronchogenic carcinoma, but the tumor masses were small and did not interfere with 
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Vmai Gaw/tGV INSP. WORK of 50% VC RESIST. BREATHING quantitation of emphysema, nor the pulmonary function studies. The lungs were inflated and fixed by formalin steam. 1 * Emphysema was quantitated by the point-counting method, and bronchial gland hyperplasia by the bronchial gland-bronchial wall ratio (Reid index). Patients were also divided into those with mild or no emphysema (20 percent or less) and those with severe emphysema (50 percent or more) on bases of physiologic methods. This separation is possible by the use of the single breath diffusing capacity and recoil pressure at total lung capacity. 8 When both are abnormal, emphysema is severe, and when both are normal there is either no emphysema or emphysema is less than 20 percent of lung parenchyma.
RESULTS
Changes after use of isoproterenol for various tests in 25 patients are shown in Figure 2 . The percent increase in FEVi was less than for mid flows, work of breathing, and airway resistance. Mean improvement in FEVi was 11 percent; FEF25-7.5, 22 percent; V max 50 percent VC, 24 percent; work of breathing, 27 percent; inspiratory resistance, 40 percent; GW/TGV, 16 percent. Seven of 25 patients showed a decrease in conductance. All of these seven patients had evidence of airway collapse even at low flow rates of 0.5L/sec in that the record showed they reached flow plateaus at this flow. In these 25 patients, total lung capacity and recoil pressure showed no significant change from pretreatment value. As expected, vital capacity increased and residual volume and functional residual capacity decreased.
For the patients as a whole, percent increase for FEF25-75 (corrected for volume) and FEVi had high correlation (r = .71, Fig 3) . The percent increase in FEF25-75 was more than twice that for FEVi, however. For the rest of the results FEF25-75 was used to assess the change after isoproterenol inhalation. The volume corrected FEF25-75 will be referred to as isovolume FEF25-75. Figure 4 relates the increase in flow rates to pathologic examination of the lung. Patients with emphysema above 20 percent had an increase in FEF25-75 of 15 percent, and those below 20 percent emphysema, FEF25--5 increased by 19 percent. These differences are not significant. Patients with a normal Reid index had a small increase (8 percent) , as compared to patients with elevated Reid index (25 percent) (.05>P>.02). • Further analysis showed this difference to be due to the patients who had severe reduction in Pst (%N TLC/Pst greater than 10). Patients with normal recoil pressure (Pst) and moderate reduction in Pst had a similar increase in FEF25-75 after isoproterenol therapy, but in patients with severe reduction in Pst improvement in FEF23-75 was significantly less (Fig 6) (P<.01) . In 39 patients with Pst measurements inspiratory pulmonary resistance was measured before and after treatment in addition to FEF2.5-75. In this group of 39 patients, those with severe reduction in Pst had lesser response in midflow, but equal improvement in inspiratory resistance after treatment, as compared to those with normal or moderately reduced Pst (Fig  7) . Thus, the lack of improvement in FEF25-75 cannot be attributed to irreversible airway disease in these patients. Patients with elevated airway resistance had a similar increase in forced expiratory flow rates to those with normal airway resistance (Fig 8) .
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Thirty-six patients were restudied after an interval of 12-36 months. The mean increase in FEF25-75 on the first study was 36 percent, and on the second study 26 percent. Considering greater than 20 percent increase in FEF25-75 after use of isoproterenol as representing good response, and below 20 percent as poor response, 25 patients responded well on the first study and 11 patients responded poorly. Of the 25 patients who showed good response on the first study, 12 showed poor response on the second study, and of the 11 patients with poor response on the first study four showed good response on the second study.
The difference between the first and second study was not statistically significant, but this may suggest that response to isoproterenol therapy is diminished later in the course of the disease. To examine this point further, changes in FEF25-75 after use of isoproterenol were plotted against FEVi percent of normal. The changes in flow rates, after isoproterenol therapy were not related to the severity of the disease as judged by FEVi except in patients with minimal evidence of airway obstruction. The increase in FEF25-75 was identical in patients with "Wheezing" and "attacks of bronchospasm" are usually associated with reversible airway obstruction. In Figure 9 , patients with COPD and wheezing on auscultation of the chest during spontaneous breathing are compared to those without wheezing, and patients with COPD and a history of "asthmatic attacks" to those without such a history. Only patients seen and examined by the author were included in this evaluation to minimize observer variability. A patient was considered to have "asthmatic attacks" if he gave a history of episodic periods of wheezing and shortness of breath. Patients with "wheezing" on auscultation and those with "asthmatic attacks" had a higher increase in FEF25-75, as compared to patients without these findings. It should be noted that wheezing was frequently present in these patients (128 of 155 had wheezing). Figure 10 shows changes in flow rates which were virtually identical in patients who stated they improved after the treatment, as compared to those who stated they did not (25 and 32 percent).
DISCUSSION
The degree of change in function studies after administration of isoproterenol can vary, depending on the interval between treatments, duration between treatment and performance of the test, 15 and the test used. 3, 16, 17 Bronchodilator therapy was stopped ten hours before the study in all patients in this series, and post-treatment tests done 20 to 30 minutes after beginning of treatment when maximal response is reported to occur. 15 Maximum midflow rate (FEF25-75) adjusted for changes in lung volume, was used to assess response to therapy in this series. When compared with maximum midflow rate from flow volume curves, the results are comparable (Fig 2) . Bouhuys, et al, 16 reported flow rates measured at the same lung volume to be the most sensitive test in assessing the response to bronchodilators when the diseased airways are the small airways, which is the case in COPD. 18 Ideally, measurements of flow rates are best done in conjunction with determination of total lung capacity; however, total lung capacity showed no change after use of isoproterenol in 25 patients in this series, and this experience is similar to others. whole, patients with history of episodic wheezing and shortness of breath "asthma attacks," and patients with wheezing on auscultation of chest during spontaneous breathing, showed greater improvement after treatment as compared to patients without such findings. For both portions of the graph, the difference was significant (P<.02). It is desirable to have such correlation on a larger number of patients. Recently we have shown that separation of patients into those with severe emphysema (more than 50 percent) from those with mild or no emphysema (20 percent or less) can be made by physiologic tests. 8 Therefore, the patients were divided on the bases of Pst and DL/L into those with severe emphysema (more than 50 percent), and those with no emphysema or mild emphysema (20 percent was significantly less in patients with physiologic evidence of severe emphysema. This was due to the small change in FEF25-75 in patients with severe reduction in Pst (%N TLC/Pst > 10), while the response in patients with moderate reduction in Pst (%N TLC/Pst 6-9) was similar to patients with normal Pst. Both groups of patients with moderate and severe reduction in Pst should have severe emphysema (more than 50 percent). Furthermore the lack of improvement in flow rates in patients with severe reduction in Pst cannot be interpreted as lack of response to therapy in these patients, since inspiratory pulmonary resistance showed equal improvement with use of isoproterenol in them, as compared to patients with more normal Pst (Fig 7) . The lack of response in expiratory forced mid flow rates must be explained on different bases than lack of response to therapy. The equal pressure point (EPP) concept of Mead et al 20 can be used to offer an explanation. In patients with severe reduction in Pst and increased airway resistance, the EPP is located further upstream from the carina, as compared to patients with lesser reduction in Pst. After bronchodilator therapy relaxation of bronchial smooth muscles renders the large airways more collapsible and the EPP moves toward the carina. 21 Thus, after therapy the upstream segment is longer in patients with severe reduction in Pst as compared to patients with more normal Pst. This increases the resistance of this segment and reduces or overcomes the bronchodilation effect on the small airways. isoproterenol could be reduction in recoil pressure after therapy as reported by McFadden et al. 2Z These authors delivered large doses of isoproterenol, which presumably caused muscular relaxation and dilatation of the terminal lung units. When they used smaller concentrations of isoproterenol, as the one used in this study, lung recoil pressure did not change. In 25 patients in this series there were no systematic changes in lung recoil at TLC. Therefore, in this study, reduction in recoil pressure after use of bronchodilators cannot be implicated as the cause of the minimal change in flow rates observed in some patients.
It is clear that measurements of forced expiratory flow rates may increase, decrease, or show no change after bronchodilator therapy, depending on whether bronchodilation of small airways or increased collapsibility of large airways predominate.
Changes in Airway Resistance after Bronchodilator Therapy
Inspiratory pulmonary resistance is not affected by changes in collapsibility of the large airways and should be a useful test to measure bronchodilator response. This is especially the case in patients with severe reduction in recoil pressure. A recent report by Bouhuys et al 10 showed no change in airway resistance after administration of bronchodilators, while midflow rates showed significant improvement. Thus, in some patients changes in small airways may not be reflected by measurements of airway resistance alone. For a more adequate evaluation of the effect of bronchodilator treatment, both expiratory mid flow rates and airway resistance should be used.
Airway resistance by body plethysmography is measured at low flow rates and usually before flow plateaus occur. Under these conditions airway resistance is comparable to inspiratory pulmonary resistance. 23 In some patients with severe COPD, flow plateaus occur even at flow rates of 0.5 L/sec, and measurement of airway resistance in these patients can show considerable variability 24 and may be influenced by increased collapsibility of large airways. In seven patients, specific conductance decreased after bronchodilator therapy (Fig  2) . All these patients showed flow plateaus at flow of 0.5 L/sec. In such patients inspiratory pulmonary resistance should be a more reliable test for measuring the response to bronchodilators. It should be mentioned that with body plethysmography, it is possible to measure both inspiratory and expiratory resistance separately.
Clinical
Relevance of Determining Response to Bronchodilators
Clinically, the response to bronchodilator therapy did not correlate with the patient's own assessment of benefit from the treatment. In general, patients with wheezing and with episodes of bronchospasm can be expected to show more improvement in flow rates after therapy, as compared to patients without such findings. Enormous variability was present between patients, however. In addition, patients who do not show improvement on one occasion may show improvement on another, and according to Curtis et al,° almost all patients with COPD will show good response when tested on more than one occasion. Assessed on one occasion, the response to bronchodilator therapy cannot be relied upon to determine the reversibility or irreversibility of COPD, nor to predict the clinical benefit from such therapy. Crompton 25 did not find the response to isoproterenol to be helpful in selecting patients likely to benefit from steroid therapy. It is possible that multiple assessments of the response to bronchodilator therapy might be of more clinical value.
